drugset

drugset / Trial / NCT00591136

Phase I Study of Indibulin in Patients With Solid Tumors

NCT00591136 ↗

Phase 1 Completed 47 enrolled Alaunos Therapeutics

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.

Timeline

Start: 2003-04
Primary completion: 2008-09
Completion: 2008-09

Publications

Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	indibulin	Small molecule	—	Oral

Indications